Drugs / O-CHLOROACETYLCARBAMOYLFUMAGILLOL
O-CHLOROACETYLCARBAMOYLFUMAGILLOL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000763 | ? → Feb 1997 | HIV infectious disease, Kaposi's sarcoma | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00038701 | Aug 1999 → May 2004 | pancreatic neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | O-CHLOROACETYLCARBAMOYLFUMAGILLOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL424278 ↗ |
| Known as | AGM-1470 | ChEMBL registry synonym — accepted as the source's own label CHEMBL424278 ↗ |
| Known as | NSC-642492 | ChEMBL registry synonym — accepted as the source's own label CHEMBL424278 ↗ |
| Known as | TNP-470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00038701 ↗ |
| Action | Inhibit | “drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with the disease.” NCT00000763 ↗ |
| Modality | Small molecule | — CHEMBL424278 ↗ |
| Route | Intravenous | “intravenous TNP-470” NCT00000763 ↗ |